DDInter348 DDInter1435
Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Chenodeoxycholic acid {u} (Compound) resembles {v} (Compound) Ursodeoxycholic acid
Chenodeoxycholic acid {u} (Compound) treats {v} (Disease) primary biliary cirrhosis
Chenodeoxycholic acid {u} (Compound) binds {v} (Gene) CYP27A1
Chenodeoxycholic acid {u} (Compound) downregulates {v} (Gene) SHB
Chenodeoxycholic acid {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Chenodeoxycholic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Chenodeoxycholic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Chenodeoxycholic acid {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Chenodeoxycholic acid {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Chenodeoxycholic acid (Compound) resembles Ursodeoxycholic acid (Compound)
Chenodeoxycholic acid (Compound) treats primary biliary cirrhosis (Disease)
Chenodeoxycholic acid (Compound) binds CYP27A1 (Gene)
Chenodeoxycholic acid (Compound) downregulates SHB (Gene)
Chenodeoxycholic acid (Compound) causes Myocardial infarction (Side Effect)
Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Chenodeoxycholic acid may lead to a major life threatening interaction when taken with Teriflunomide
Chenodeoxycholic acid may lead to a major life threatening interaction when taken with Mipomersen